SEC Company Response from Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166) (BGMS) — Apr 16, 2020
Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166)
Date: April 16, 2020 · CIK: 0001130166 · Accession: 0001104659-20-047707
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-237180
Letter
CYCLACEL PHARMACEUTICALS, INC.
200 Connell Drive, Suite 1500
Berkeley Heights, NJ 07922
April 16, 2020
Via EDGAR
William Mastrianna
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Cyclacel Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed on March 13, 2020, as amended on April 14, 2020
File No. 333-237180
Acceleration Request
Mr. Mastrianna:
Pursuant to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Cyclacel Pharmaceuticals, Inc. (the “Company”) hereby requests that the effectiveness of the above-captioned Registration Statement on Form S-1 be accelerated to Monday, April 20, 2020, at 4:30 p.m., EST, or as soon as thereafter practicable.
Any questions should be addressed to Joel I. Papernik, Esq., at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Chrysler Center, 666 Third Avenue, New York, New York, telephone (212) 692-6774.
Thank you for your attention to this matter.
Very truly yours,
Cyclacel Pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
CYCLACEL PHARMACEUTICALS, INC.
200 Connell Drive, Suite 1500
Berkeley Heights,
NJ 07922
April 16, 2020
Via EDGAR
William Mastrianna
Securities and Exchange
Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Cyclacel Pharmaceuticals, Inc.
Registration
Statement on Form S-1
Filed
on March 13, 2020, as amended on April 14, 2020
File
No. 333-237180
Acceleration
Request
Mr. Mastrianna:
Pursuant
to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Cyclacel Pharmaceuticals, Inc.
(the “Company”) hereby requests that the effectiveness of the above-captioned Registration Statement on Form S-1 be
accelerated to Monday, April 20, 2020, at 4:30 p.m., EST, or as soon as thereafter practicable.
Any questions should
be addressed to Joel I. Papernik, Esq., at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Chrysler Center, 666 Third Avenue,
New York, New York, telephone (212) 692-6774.
Thank
you for your attention to this matter.
Very truly yours,
Cyclacel Pharmaceuticals, Inc.
/s/ Spiro Rombotis
Spiro Rombotis
Chief Executive Officer
cc: Cyclacel Pharmaceuticals, Inc.
Paul
McBarron